Stock Yearly Return 2015
Start date: 12/31/2014
End date: 12/31/2015
Start price/share: $9.83
End price/share: $1.69
Dividends collected/share: $0.00
Total return: -82.81%
Average Annual Total Return: -82.81%
Starting investment: $10,000.00
Ending investment: $1,719.00
Years: 1.00


CBAY average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Compare CBAY average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Growth of $10,000.00
Without Dividends Reinvested Into CBAY


Also see:
CBAY stock yearly return 2016
CBAY stock yearly return 2017
CBAY stock yearly return 2018
CBAY stock yearly return 2019
CBAY stock yearly return 2020
CBAY YTD return
CBAY average annual return 10 years
CymaBay Therapeutics is a biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other diseases. Co.'s pipeline includes two clinical stage product candidates: seladelpar (MBX-8025), which is a selective agonist for the peroxisome proliferator-activated receptor delta and has the potential to treat certain diseases of the liver and disorders of lipid metabolism; and MBX-2982, which targets G protein-coupled receptor 119, a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. Co. has one preclinical stage product candidate, CB-001, which targets G protein-coupled receptor 120. The CBAY stock yearly return is shown above.

The yearly return on the CBAY stock yearly return page and across the coverage universe of our site, is a measure of the annual return over the calendar year 2015 for the given stock. When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is more than just the change in price if that instrument pays a dividend or coupon.

One way to factor dividends into the return is simply to count them as cash — we don't do that here. Instead, our website aims to empower investors by performing the CBAY annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes
Get Free SEC filing alerts for CBAY:
CBAY SEC Filing Email Alerts ServiceExternal link
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
CymaBay Therapeutics (CBAY) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

CBIO Average Annual Return
CBLI Average Annual Return
CBM Average Annual Return
CBMG Average Annual Return
CBPO Average Annual Return
CCRN Average Annual Return
CCXI Average Annual Return
CDMO Average Annual Return
CDNA Average Annual Return
CDTX Average Annual Return
More Healthcare companies »

 

CBAY Stock Yearly Return 2015 | www.AverageAnnualReturn.com | Copyright © 2021 - 2021, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.